IRD Opus Genetics, Inc.
Opus Genetics, Inc. (IRD) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 2% planned / 98% discretionary
Largest single sale: $2.8M.
Where they traded
Last open-market purchase: December 29, 2025 , by Gallagher Cam .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Magrath George | Chief Executive Officer | Sell | 28,258 | $3.90 | $110.2K | 2,010,636 −1.4% of holding | |
| YERXA BENJAMIN R 2 fills | President | Sell | 33,189 | $3.54 | $117.4K | 696,437 −4.5% of holding | |
| Gagnon Robert E. | Chief Financial Officer | Sell 10b5-1 | 14,000 | $3.55 | $49.6K | 542,375 −2.5% of holding | |
| Magrath George | Chief Executive Officer | Sell | 9,591 | $3.58 | $34.4K | 2,038,894 −0.5% of holding | |
| SCHACHLE JOSEPH K | Chief Operating Officer | Sell | 4,767 | $3.57 | $17.0K | 286,673 −1.6% of holding | |
| Sell | 556,000 | $4.96 | $2.8M | 3,236,171 −14.7% of holding | |||
| Gagnon Robert E. | Chief Financial Officer | Sell | 28,000 | $4.54 | $127.2K | 556,375 −4.8% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.